市場調査レポート

商品コード

1681598

生物製剤の市場規模、シェア、成長分析：タイプ別、薬剤クラス別、治療用途別、供給源別、製造業別、地域別 - 産業予測 2025年-2032年

Biologics Market Size, Share, and Growth Analysis, By Type (Tumor Necrosis Factor Inhibitor, T-cell Inhibitor), By Drug Class, By Therapeutic Application, By Source, By Manufacturing, By Region - Industry Forecast 2025-2032

出版日: 2025年03月09日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

生物製剤市場規模は2023年に5,113億米ドルと評価され、2024年の5,675億4,000万米ドルから2032年には1兆3,079億2,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは11.0％で成長する見通しです。

世界の生物製剤市場は、バイオテクノロジーの進歩や標的治療に対する需要の高まりに牽引され、堅調な成長を示しています。生物由来の医薬化合物である生物製剤は、がん、自己免疫疾患、感染症などの慢性疾患治療の展望を大きく変えました。そのオーダーメイドで革新的なアプローチは患者の予後を向上させ、バイオ医薬品を現代ヘルスケアにおける重要な要素として位置づけています。市場成長の主な促進要因としては、糖尿病や関節炎などの慢性疾患の蔓延が深刻化し、効果的な治療オプションが必要とされていることが挙げられます。しかし、温度や環境条件の影響を受け、サプライチェーン全体を通してこれらの生物製剤の完全性を維持することに課題が残っています。米国の生物製剤市場は持続的な成長が見込まれており、QOLの向上や疾病管理におけるバイオ医薬品の有望な可能性を示しています。

市場概要
モノクローナル抗体
組み換えインスリン
ワクチン
血液因子
ヒト成長ホルモン
エリスロポエチン
融合タンパク質
組み換え酵素
インターフェロン
コロニー刺激因子
遺伝子治療
- 細胞療法
- オリゴヌクレオチド
- その他
ペプチド
ボツリヌス毒素
その他

生物製剤市場規模：治療用途別

市場概要
腫瘍学
自己免疫疾患/免疫疾患
代謝障害
眼科疾患
呼吸器疾患
炎症性腸疾患（IBD）
神経疾患
心血管疾患（CVD）
筋骨格障害（MSD）
感染症
その他

生物製剤市場規模：供給源別

市場概要
微生物
哺乳類
その他

生物製剤市場規模：製造業別

市場概要
アウトソーシング
社内製造

生物製剤市場規模：薬の種類別

市場概要
ブランド医薬品
ジェネリック医薬品

生物製剤市場規模：購入方法別

市場概要
処方薬
市販薬（OTC）

生物製剤市場規模：剤形別

市場概要
注射
錠剤
その他

生物製剤市場規模：投与経路別

市場概要
非経口
経口
その他

生物製剤市場規模：エンドユーザー別

市場概要
病院
専門クリニック
ホームケア
その他

生物製剤市場規模：流通チャネル別

市場概要
病院薬局
小売薬局
オンライン薬局
その他

生物製剤市場規模

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022～2024年）

主要企業プロファイル

Roche Holding AG（Switzerland）
Johnson & Johnson（USA）
AbbVie Inc.（USA）
Novartis AG（Switzerland）
Amgen Inc.（USA）
Merck & Co., Inc.（USA）
Bristol Myers Squibb（USA）
Eli Lilly and Company（USA）
AstraZeneca plc（UK）
Biogen Inc.（USA）
Gilead Sciences, Inc.（USA）
Regeneron Pharmaceuticals, Inc.（USA）
Takeda Pharmaceutical Company Limited（Japan）
Boehringer Ingelheim（Germany）
Samsung Biologics（South Korea）
Lonza Group AG（Switzerland）
WuXi Biologics（China）
Celltrion, Inc.（South Korea）
Grifols, S.A.（Spain）

結論と提言

Product Code: SQMIG35H2127

Biologics Market size was valued at USD 511.3 billion in 2023 and is poised to grow from USD 567.54 billion in 2024 to USD 1307.92 billion by 2032, growing at a CAGR of 11.0% during the forecast period (2025-2032).

The global biologics market has demonstrated robust growth, driven by advancements in biotechnology and the rising demand for targeted therapies. Biologics, pharmaceutical compounds sourced from living organisms, have shifted the landscape of treatment for chronic conditions, including cancer, autoimmune disorders, and infectious diseases. Their tailored and innovative approaches enhance patient outcomes, positioning biopharmaceuticals as critical components in modern healthcare. Key market growth drivers include the escalating prevalence of chronic diseases, such as diabetes and arthritis, necessitating effective treatment options. However, challenges remain in maintaining the integrity of these biologics throughout the supply chain, influenced by temperature and environmental conditions. The US biologics market is set for sustained growth, indicating promising prospects for biopharmaceuticals in improving quality of life and disease management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biologics Market Segments Analysis

Global Biologics Market is segmented by Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel and region. Based on Type, the market is segmented into Tumor Necrosis Factor (TNF) Inhibitor, T-cell Inhibitor, Selective Co-stimulation Modulators, Interleukin-6 (IL-6) or Interleukin-17 Blocker, Interleukin-1 (IL-1) Blocker and B-cell Inhibitor. Based on Drug Class, the market is segmented into Monoclonal Antibody, Recombinant Insulin, Vaccine, Blood Factor, Human Growth Hormone, Erythropoietin, Fusion Protein, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Gene Therapy, Peptide, Botulinum Toxin and Others. Based on Therapeutic Application, the market is segmented into Oncology, Autoimmune/Immunologic Diseases, Metabolic Disorders, Ophthalmic Diseases, Respiratory Disorders, Inflammatory Bowel Diseases (IBDs), Neurological Disorders, Cardiovascular Diseases (CVDs), Musculoskeletal Disorders (MSDs), Infectious Diseases and Others. Based on Source, the market is segmented into Microbial, Mammalian and Others. Based on Manufacturing, the market is segmented into Outsourced and In-House. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on Mode of Purchase, the market is segmented into Prescription Drugs and Over-The-Counter (OTC) Drugs. Based on Dosage Form, the market is segmented into Injection, Tablets and Others. Based on Route of Administration, the market is segmented into Parenteral, Oral and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biologics Market

The rising prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, has significantly spurred the demand for innovative biological therapies. These advanced treatments leverage targeted approaches, distinguishing them from traditional chemical-based medications and enhancing their effectiveness. As a result, the biologics market is experiencing substantial growth, driven by the need for more precise and efficient therapeutic options. This trend reflects a broader shift toward personalized medicine, where tailored treatments not only improve patient outcomes but also foster ongoing advancements in biopharmaceutical research and development, further propelling the market forward.

Restraints in the Biologics Market

The biologics market faces significant challenges due to the intricate and expensive processes involved in the development and production of natural products. The stringent regulatory standards in place can limit both the affordability and accessibility of biologic therapies, ultimately hindering market growth. As companies navigate these challenges, the high costs associated with compliance and manufacturing may deter investment and innovation, which could further stifle advancements in biologic treatments. Consequently, the interplay between regulatory demands and production complexities remains a critical restraint for the biologics market, impacting its overall potential and reach in the healthcare industry.

Market Trends of the Biologics Market

The Biologics market is witnessing a significant shift towards personalized medicine, fundamentally transforming therapeutic approaches. This trend emphasizes the development of biologic therapies tailored to the unique genetic profiles and specific disease characteristics of individual patients, leading to more effective and targeted treatments. As a result, innovation in biological sciences is accelerating, with advancements in areas such as monoclonal antibodies, gene therapies, and regenerative medicine. The growing demand for precision therapies is propelling investments and research in this field, expanding the scope and applications of biologics in managing various diseases, thus positioning the market for robust growth in the coming years.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Biologics Market Size by Type & CAGR (2025-2032)

Market Overview
Tumor Necrosis Factor (TNF) Inhibitor
T-cell Inhibitor
Selective Co-stimulation Modulators
Interleukin-6 (IL-6) or Interleukin-17 Blocker
Interleukin-1 (IL-1) Blocker
B-cell Inhibitor

Global Biologics Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Monoclonal Antibody
Recombinant Insulin
Vaccine
Blood Factor
Human Growth Hormone
Erythropoietin
Fusion Protein
Recombinant Enzyme
Interferon
Colony-stimulating Factor
Gene Therapy
- Cell Therapy
- Oligonucleotides
- Others
Peptide
Botulinum Toxin
Others

Global Biologics Market Size by Therapeutic Application & CAGR (2025-2032)

Market Overview
Oncology
Autoimmune/Immunologic Diseases
Metabolic Disorders
Ophthalmic Diseases
Respiratory Disorders
Inflammatory Bowel Diseases (IBDs)
Neurological Disorders
Cardiovascular Diseases (CVDs)
Musculoskeletal Disorders (MSDs)
Infectious Diseases
Others

Global Biologics Market Size by Source & CAGR (2025-2032)

Market Overview
Microbial
Mammalian
Others

Global Biologics Market Size by Manufacturing & CAGR (2025-2032)

Market Overview
Outsourced
In-House

Global Biologics Market Size by Drug Type & CAGR (2025-2032)

Market Overview
Branded Drugs
Generic Drugs

Global Biologics Market Size by Mode of Purchase & CAGR (2025-2032)

Market Overview
Prescription Drugs
Over-The-Counter (OTC) Drugs

Global Biologics Market Size by Dosage Form & CAGR (2025-2032)

Market Overview
Injection
Tablets
Others

Global Biologics Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Parenteral
Oral
Others

Global Biologics Market Size by End-Users & CAGR (2025-2032)

Market Overview
Hospitals
Specialty Clinics
Homecare
Others

Global Biologics Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Global Biologics Market Size & CAGR (2025-2032)

North America (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
- US
- Canada
Europe (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Drug Class, Therapeutic Application, Source, Manufacturing, Drug Type, Mode of Purchase, Dosage Form, Route of Administration, End-Users, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza Group AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celltrion, Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments